Wang Shan-Shan, Zeng Xian, Wang Ya-Li, Dongzhi Zhuoma, Zhao Yu-Fen, Chen Yu-Zong
Qian Xuesen Collaborative Research Center of Astrochemistry and Space Life Sciences, Institute of Drug Discovery Technology, Ningbo University, Ningbo, Zhejiang Province, 315211, China.
Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, 201203, China.
Chin J Integr Med. 2022 Jul;28(7):627-635. doi: 10.1007/s11655-022-3573-0. Epub 2022 May 18.
To investigate how the National Health Commission of China (NHCC)-recommended Chinese medicines (CMs) modulate the major maladjustments of coronavirus disease 2019 (COVID-19), particularly the clinically observed complications and comorbidities.
By focusing on the potent targets in common with the conventional medicines, we investigated the mechanisms of 11 NHCC-recommended CMs in the modulation of the major COVID-19 pathophysiology (hyperinflammations, viral replication), complications (pain, headache) and comorbidities (hypertension, obesity, diabetes). The constituent herbs of these CMs and their chemical ingredients were from the Traditional Chinese Medicine Information Database. The experimentally-determined targets and the activity values of the chemical ingredients of these CMs were from the Natural Product Activity and Species Source Database. The approved and clinical trial drugs against these targets were searched from the Therapeutic Target Database and DrugBank Database. Pathways of the targets was obtained from Kyoto Encyclopedia of Genes and Genomes and additional literature search.
Overall, 9 CMs modulated 6 targets discovered by the COVID-19 target discovery studies, 8 and 11 CMs modulated 8 and 6 targets of the approved or clinical trial drugs for the treatment of the major COVID-19 complications and comorbidities, respectively.
The coordinated actions of each NHCC-recommended CM against a few targets of the major COVID-19 pathophysiology, complications and comorbidities, partly have common mechanisms with the conventional medicines.
探讨中国国家卫生健康委员会推荐的中药如何调节2019冠状病毒病（COVID-19）的主要失调情况，特别是临床观察到的并发症和合并症。
通过关注与传统药物共有的有效靶点，我们研究了11种国家卫生健康委员会推荐的中药在调节COVID-19主要病理生理学（炎症反应过度、病毒复制）、并发症（疼痛、头痛）和合并症（高血压、肥胖症、糖尿病）方面的机制。这些中药的组成草药及其化学成分来自中药信息数据库。这些中药化学成分的实验确定靶点和活性值来自天然产物活性和物种来源数据库。从治疗靶点数据库和药物银行数据库中搜索针对这些靶点的已批准和临床试验药物。靶点的通路从京都基因与基因组百科全书及其他文献搜索中获得。
总体而言，9种中药调节了COVID-19靶点发现研究中发现的6个靶点，8种和11种中药分别调节了治疗COVID-19主要并发症和合并症的已批准或临床试验药物的8个和6个靶点。
每种国家卫生健康委员会推荐的中药针对COVID-19主要病理生理学、并发症和合并症的几个靶点的协同作用，部分与传统药物有共同机制。
